DDInter1388 DDInter1658
Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example. Its efficacy is considered similar to other medications within the PPI class including [omeprazole], [esomeprazole], [lansoprazole], [dexlansoprazole], and [rabeprazole]. Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Pantoprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Pantoprazole {u} (Compound) binds {v} (Gene) ATP4B
Pantoprazole {u} (Compound) upregulates {v} (Gene) TCTN1
Pantoprazole {u} (Compound) downregulates {v} (Gene) ACAT2
Pantoprazole {u} (Compound) causes {v} (Side Effect) Jaundice cholestatic
Pantoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capmatinib
Pantoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cefditoren
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Pantoprazole {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Pantoprazole (Compound) resembles Omeprazole (Compound)
Pantoprazole (Compound) binds ATP4B (Gene)
Pantoprazole (Compound) upregulates TCTN1 (Gene)
Pantoprazole (Compound) downregulates ACAT2 (Gene)
Pantoprazole (Compound) causes Jaundice cholestatic (Side Effect)
Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole
Pantoprazole may lead to a major life threatening interaction when taken with Atazanavir